Type-1 immunity plays a crucial role in host defense against various tumors and infectious diseases. Here, we first demonstrated that extract of Larix Leptolepis (ELL), one of the most popular timbers at Hokkaido area in Japan, strongly activated Type-1 immunity. ELL induced production of Type-1 cytokines such as IL-12 and TNF-from bone marrow-derived dendritic cells (BMDCs) in TLR2-and TLR4-dependent manner and remarkably up-regulated the expression of MHC and co-stimulatory molecules. In addition, antigen-specific CTLs were significantly augmented by the combined administration of ELL, antigen and BMDCs. Finally, we revealed that combination therapy using ELL, antigen and BMDCs significantly inhibited the growth of established tumor in mouse model. Thus, these findings suggested that ELL would be a novel adjuvant for inducing an activation of Type-1-dependent immunity including activation of BMDCs and induction of tumor-specific CTLs, which is applicable to the therapy of cancer and infectious diseases. [146 words] 
Extracts of Larix Leptolepis effectively augments the generation of tumor antigen-specific cytotoxic T lymphocytes via activation of dendritic cells in TLR-2 and TLR-4-dependent manner

Introduction
Immune system is one of the most important machineries for maintenance of our health by elimination of "non-self" pathogens, such as bacteria, viruses, fungi, parasites, and tumors. However, chronic infection, tumor-bearing condition, aging, and malnutrition occasionally cause dysfunction of the immune system [1] [2] [3] [4] . An immunological adjuvant, which nonspecifically activates the innate immunity and subsequently induces antigen-specific immune responses, is one of the most popular methods for overcoming immunosuppressive conditions [5] . Type-1 and Type-2 immunity is involved in the regulation of cellular and humoral immunity, respectively [6] .
Type-1 immunity is crucial for the rejection of tumors and the elimination of pathogens such as viruses and bacteria [7] [8] [9] . Generally, cytotoxic T lymphocytes (CTLs) play a pivotal role as effector cells for the elimination of tumor cells and intracellular pathogen [7, 10, 11] . Thus, it is of great important to develop a novel adjuvant for enhancing
Type-1 immunity-dependent CTL-generation, essential for preventing cancer and infectious diseases. Many investigators have searched good adjuvants to activate antigen-presenting cells (APCs) [5, [12] [13] [14] .
Dendritic cells (DCs), one of the most powerful APCs, have a pivotal role for initiating immune responses [15] [16] [17] . It has been well-known that DCs take up extracellular antigens, process them into peptides, and promptly load them on major histocompatibility (MHC) class II molecules, which activate CD4 + T cells. DCs also have a unique function, called "cross-presentation", which induces protective immunity by the antigen-specific cytotoxicitic CD8 + T lymphocytes (CTLs) against tumors and intracellular infectious microbes [18] . For example, systemic chronic infection of malaria significantly reduced T cell responses, but the antigen-loaded DCs could break the immune-suppressive condition [19] . In addition, adoptive cell transfer with tumor-antigen-loaded DCs is one of the most powerful methods for the therapy of cancers [15, 20, 21] .
Larix Leptolepis (Larix kaempferi), deciduous and conifer tree planting at subarctic zone, is useful as architectural material in Japan. We have carried out research to seek novel functional materials from the sawdust of Larix Leptolepis. In the present work, we found that extract of Larix Leptolepis (ELL) from Japan remarkably activated DCs and effectively enhanced the generation of tumor antigen-specific CTLs, suggesting it will become a novel promising adjuvant to potentiate Type-1-dependent cellular immunity.
.
Materials and methods
Mice
Wild-type (WT) C57BL/6 mice were purchased from Charles River Japan (Yokohama, Japan). C57BL/6-background TLR2 −/− , TLR4 −/− , and TLR9 −/− mice were kindly provided by Dr. S. Akira (Department Host defense, Research Institute for Microbial Disease.
Osaka University, Osaka, Japan). OVA 323-339 -specific I-A b -restricted T cell receptor transgenic mice (OT-II) on the C57BL/6 background were kindly donated by F.R.
Carbone (University of Melbourne, Victoria, Australia). All mice were maintained in specific pathogen-free conditions according to the guideline of animal department at Hokkaido University and used at 6-8 weeks of age.
Antibodies and reagents
APC-conjugated anti-CD11c monoclonal antibody (mAb) (HL3), and anti-CD4 mAb (GK1.5), PE-conjugated anti-IL-12p40/70 mAb (C15.6), and anti-IFN- mAb (XMG1.2), and anti-IL-4 mAb (11B11), FITC-conjugated anti-TNF-mAb (MP6-XT22), and anti-CD8 mAb (AF6-88.5) were purchased from BD bioscience (San Diego, USA).
7-amino-actinomycin D (7AAD) was purchased from Beckman coulter (Miami, USA).
OVA protein was purchased from Sigma-Aldrich Japan (Tokyo, Japan). H-2K b OVA tetramer-SIINFEKL-PE (OVA tetramer) was purchased from MBL (Nagoya, Japan). IL-2 was kindly supplied by Takuko Sawada (Shionogi Pharmaceutical Institute Co. Ltd., Osaka, Japan).
Preparation of ELL
Larix Leptolepis was crushed to sawdust and beated up with pure water for 1 hour. Next, to remove low molecular weight components, the extract was dialyzed extensively against water and lyophilized. The final LPS contents in the ELL was less than 6.25 pg / mg detected by the Toxicolor test (Seikagaku Kogyo Co., Tokyo, Japan).
Generation of bone marrow-derived dendritic cells (BMDCs).
Bone marrow (BM) cells were prepared from WT, TLR2
-/-, TLR4
-/-, and TLR9 -/-mice.
BMDCs were generated from BM cells with RPMI medium (Sigma Aldrich, Germany)
containing 10% FCS (BD Bioscience) in the presence of GM-CSF (20 ng/ml) as described previously [22] . Loosely adherent clustering cells were harvested on day 6-8.
CD11c
+ BMDCs were isolated with anti-CD11c micro beads and used in the present experiments.
Flow cytometry
For analysis of cell surface molecules, BMDCs were stimulated with or without ELL (2, 5, 
ELISA
BMDCs were stimulated with or without ELL (10 mg/ml) for 12 hrs. were prepared from popliteal lymph nodes and stained with FITC-conjugated anti-CD8 mAb and PE-conjugated OVA tetramer for analysis of OVA-specific CTLs.
Cytotoxicity assay
The cytotoxicity mediated by tumor-specific CTLs was measured by a 6 hr 51
Cr-release assay, as described previously [13] . Briefly, 51 Cr-labeled target cells were cocultured with various numbers of effector cells for 6 hr in V-bottomed microtiter plates. Released 51 Cr in the culture supernatants were measured by gamma counter (Packard Cobra II gamma counter, Meriden, CT, USA) and the percentage of specific lysis was calculated.
Immunotherapy for transplanted tumor
OVA-expressing EG7 cells (2x10 
Statistical analyses
All experiments were repeated at least three times. Mean values and SDs were calculated for the data from representative experiment and shown in the figures.
Significant differences in the results were determined by the Student's t-test. The p<0.05
was considered as significant in the present experiments.
Results
ELL induces production Type-1 cytokines from BMDCs.
Type-1 cytokines such as IL-12 and TNF- are closely related with activation of Type-1 immunity [23, 24] . To evaluate the immunomodulating potential of ELL, we examined whether ELL induce production of IL-12 and TNF- from BMDCs. BMDCs prepared from WT C57BL/6 mice were cultured in the presence or absence of ELL for 12 hrs and cytokine producing BMDCs were detected by flow cytometry. As a result, the percentages of IL-12-or TNF--producing DCs were increased by stimulation with ELL in a dose dependent manner (Fig. 1A) . Here, we confirmed that ELL has no significant toxicity against thymocytes. (data not shown). In addition, BMDCs were stimulated with ELL for 24 hrs and cytokine levels in the culture supernatants were determined by ELISA. Consistent with the intracellular staining analysis, we confirmed that ELL strongly induced IL-12 and TNF- production from BMDCs (Fig. 1B) . IL-10 and IL-4
were not detected by intracellular staining. However, IL-10 was detected by ELISA in culture supernatants though its levels are greatly low (data not shown). These findings suggested that ELL directly stimulated dendritic cells and activated Type-1 immunity.
ELL induces activation of BMDCs in TLR2-and TLR4-dependent manners.
It has been well demonstrated that BMDCs express various pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs), which is critical for host defense against bacteria and viruses [25] . To address the activation mechanisms of BMDC by ELL, we examined the contribution of TLRs (TLR2, TLR4 and TLR9) to the cytokine production by BMDCs after stimulation with ELL. BMDCs prepared from WT, TLR2
-/-, TLR4 -/-and TLR9 -/-mice were stimulated with ELL for 24 hrs. We found that IL-12 and TNF- production was markedly decreased in TLR2-or TLR4-deficient BMDCs in comparison with WT or TLR9-deficient BMDCs (Fig. 2) . These data clearly demonstrated that TLR2 and TLR4 are involved in the activation of BMDCs after ELL stimulation.
ELL significantly causes maturation of BMDCs.
Stimulation signals from TLRs induce maturation of DCs and augment expression of MHC class I and class II molecules [26] . In addition, costimulatory molecules are highly expressed on the matured DCs, which are indispensable for fully activation of T cells. It has been indicated that CD86 and CD40 are especially important molecules for activation of Type-1 immunity [27] [28] [29] . Therefore, we examined the expression levels of MHC class I, MHC class II, CD86, and CD40 on DCs after BMDCs were cultured with ELL for 24 hrs. As a result, ELL-stimulated DCs exhibited elevated expression of these molecules compared with non-stimulated DCs (Fig. 3A) . We further stimulated BMDCs with various concentration of ELL and confirmed that ELL enhanced expression levels of MHC class I, MHC class II, CD86, and CD40 molecules on the cell surface of BMDCs in a dose-dependent manner (Fig. 3B ). In addition, we examined that effect of ELL in Th1/Th2 differentiation. Naïve OT-II cells were stimulated with OVA-peptide in the presence or absence of ELL. In Day4, these cells were stimulated with immobilize anti-CD3 mAb. As a result, ELL strongly enhances efficiency of Th1 cells and suppressed of Th2. (Fig. 3C) . Thus, these data suggested that ELL would activate T cell-mediated Type-1 immune responses via maturation of DCs.
Administration of ELL with BMDCs efficiently induces antigen-specific CTLs in vivo.
To investigate whether ELL act as an adjuvant to induce antigen-specific CTLs in vivo,
we immunized in the footpad of C57BL/6 mice with ELL, BMDCs and ovalbumin (OVA) twice 5 days intervals. The lymphocytes were prepared from popliteal lymph nodes 5 days after final immunization to examine the generation of OVA-specific CTLs by staining with OVA tetramer. In the mice treated with DCs+OVA+ELL, the percentages and total numbers of OVA tetramer + CD8 + CTLs were significantly increased compared with other immunization groups (Fig. 4A, 4B) . Moreover, we examined the cytotoxic activity of CTL against EG7. As a result, administration of ELL strongly enhanced CTL function (Fig. 4C) . Therefore, these findings indicated that ELL would be a useful adjuvant for vaccine therapy for cancer. (Fig. 5) . Although the mice treated with DCs+OVA and OVA+ELL also exhibited antitumor effects, DC vaccine therapy combined with ELL (DCs+OVA+ELL) were most potent therapeutic effects than other groups. We also confirmed that high percentages of OVA tetramer + CTLs infiltrated into tumor tissue of mice treated with DC+OVA+ELL (data no shown). Taken together, our data strongly indicated that ELL is a promising adjuvant for cancer immunotherapy.
DC vaccine therapy combined with ELL effectively inhibits tumor growth
Discussion
In this article, we have shown that ELL is a potent adjuvant that can selectively induce Cross-presentation of exogenous antigen by DCs is an important mechanism in activation of CD8 + T cell-mediated immunity [56, 57] . Several reports demonstrated that TLR ligand promoted endosomal acidification, proteasomal activity, and TAP translocation in DCs, resulting in the efficient presentation of exogenous antigen and enhancement of CTL activation [58] [59] [60] [61] . Therefore, promotion of cross-presentation would be involved in CTL induction by vaccination with ELL.
It is known that stimulation with multiple TLRs effectively activates DCs and subsequently induces strong T cell responses [62] . For example, the yellow fever vaccine YF-17D, one of the most successful empiric vaccines, activates dendritic cells via multiple TLRs [63] . In the present work, we finally revealed that adoptive transfer of DCs with ELL remarkably inhibited tumor growth in the tumor-bearing mice ( Figure 5 ).
The marked antitumor effects of ELL might be due to the synergistic impact of TLR2 and TLR4 ligand in ELL. Previously we demonstrated that in vivo administration of TLR9 ligand, CpG-ODN, up-regulated Type-1 immunity, also remarkably caused tumor regression [13, 64] . Thus, combination therapy of CpG-ODN and novel TLR ligands in ELL would be useful for therapeutic strategies of tumor and infectious diseases via induction of antigen-specific CTL induction. was measured by 51 Cr-release assay. The means and SDs were calculated from the representative data of three independent experiments and indicated in the figure.
Asterisks mean p < 0.05 show significant differences against the data of DC+OVA (**), OVA (*). 
